TABLE 1.
Baseline patient characteristics
| Variables | n = 278 (%) |
|---|---|
| Age | 68.5 (61‐74) |
| Sex | |
| Male | 185 (66.6) |
| Female | 93 (33.5) |
| Eastern cooperative oncology group performance status (ECOG PS) | |
| 0 | 143 (51.4) |
| 1 | 122 (43.9) |
| 2 | 13 (4.7) |
| Type of cancer | |
| Primary | 133 (47.8) |
| Recurrence | 145 (52.1) |
| Esophagogastric junction cancer (Siewert type) | |
| Type 1 | 6 (2.2) |
| Type 2 | 29 (10.4) |
| Type 3 | 12 (4.3) |
| Metastatic site | |
| Peritoneum | 117 (42.1) |
| Liver | 82 (29.5) |
| Lung | 23 (8.3) |
| Lymph node | 89 (32.0) |
| Pathological type | |
| Differentiated | 130 (46.8) |
| Undifferentiated | 147 (52.9) |
| Unknown | 1 (0.4) |
| Human epidermal growth factor 2 (HER2) status | |
| Positive | 59 (21.2) |
| Negative | 184 (66.2) |
| Unknown | 35 (12.6) |
| Number of prior regimens a | |
| ≤2 | 183 (65.8) |
| 3 | 72 (25.9) |
| ≥4 | 23 (8.3) |
| Prior regimens | |
| Taxane agents | 242 (87.1) |
| Irinotecan | 33 (11.9) |
| Ramucirumab | 216 (77.7) |
| Post nivolumab treatment | |
| Nivolumab continuation | 14 (5.0) |
| Irinotecan b | 61 (21.9) |
| Trifluridine/Tipiracil b | 25 (9.0) |
| Taxane agents b | 6 (2.2) |
| Other regimens b | 17 (6.1) |
| Best supportive care | 160 (57.6) |
a
Includes treatments received in the adjuvant setting.
b
Including overlap.